Abstracts tagged "Biologics"

Abstract Number: 579 • 2014 ACR/ARHP Annual Meeting
Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the ‘then Test’ in Patients Treated with TNF-Inhibitors
Ivette Essers¹, Astrid Van Tubergen^1,2, Jurgen Braun³, Xenofon Baraliakos³, Frank Heldmann³ and Annelies Boonen^4,5, ¹School for Public Health and Primary Care (CAPHRI), Maastricht University, Maastricht, Netherlands, ²Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands
Background/Purpose: Although never formally studied, rheumatologists feel that patients with ankylosing spondylitis (AS) tend to adjust to their disease. Response shift is one of the…
Abstract Number: 1943 • 2014 ACR/ARHP Annual Meeting
In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice
Carolin Brandl*¹, Lamia Özgör*¹, Miriam Wöhner^1,2, Anthony Shock³ and Lars Nitschke¹, ¹Division of Genetics, University of Erlangen, Erlangen, Germany, ²Research Institute of Molecular Pathology, Vienna, Austria, ³UCB Pharma, Slough, United Kingdom
Background/Purpose Epratuzumab is a humanized monoclonal antibody that targets the B cell-specific protein CD22 currently in Phase 3 clinical trials in patients (pts) with systemic…
Abstract Number: 1358 • 2014 ACR/ARHP Annual Meeting
A Systematic Analysis of the Safety of Prescribing Anti-Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women
Sonia Panchal¹, Julia Flint², Maud van de Venne³, Madeline Piper⁴, Alice Hurrel⁵, Joel Cunningham⁵, Mary Gayed⁶, Karen Schreiber⁷, Subha Anthanari⁸, Mohamed Nisar⁸, David Williams⁹, Munther Khamashta¹⁰, Caroline Gordon¹¹ and Ian Giles², ¹Rheumatology, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom, ²UCL Division of Medicine, University College London, London, United Kingdom, ³Obstetrics and Gynaecology, North Bristol NHS Trust, Bristol, United Kingdom, ⁴Ysbyty Ystrad Fawr, Aneurin Bevan Health Board Wales, Wales, United Kingdom, ⁵Institute for Women's Health, University College London, London, United Kingdom, ⁶Rheumatology Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom, ⁷Lupus Research Unit, Division of Infection and Immunity, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁸Rheumatology, Burton Hospitals NHS Foundation Trust, Burton-upon-Trent, United Kingdom, ⁹University College London, London, United Kingdom, ¹⁰Lupus Research Unit, Division of Women's Health, Guy's and St Thomas' NSH Foundation Trust, London, United Kingdom, ¹¹Rheumatology, Division of Infection and Immunity, The Medical School, University of Birmingham, Birmingham, United Kingdom
Background/Purpose The use of anti-rheumatic drugs in pregnancy is often complicated by concerns over their potential for adverse effects. Given that rheumatic diseases often affect…
Abstract Number: 518 • 2014 ACR/ARHP Annual Meeting
Risk of Infection Associated with Subsequent Biologic Use Following Rituximab—Results from a National RA Patient Registry
Leslie R. Harrold¹, George W. Reed^1,2, Chitra Karki³, Robert Magner¹, Ashwini Shewade⁴, Ani John⁴, Joel M. Kremer⁵ and Jeffrey D. Greenberg^3,6, ¹University of Massachusetts Medical School, Worcester, MA, ²Corrona, LLC., Southborough, MA, ³Corrona, LLC, Southborough, MA, ⁴Genentech, Inc, South San Francisco, CA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Rituximab is a chimeric monoclonal antibody for the treatment of rheumatoid arthritis (RA). Prolonged B-cell depletion from repeated doses of rituximab may be associated…
Abstract Number: 2938 • 2014 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 16-Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis
J Sieper¹, D van der Heijde², M Dougados³, Walter P. Maksymowych⁴, J Boice⁵, G Bergman⁵, S Curtis⁵, A Tzontcheva⁵, S Huyck⁵ and HH Weng⁵, ¹University Clinic Benjamin Franklin, Berlin, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Paris-Descartes University, Paris, France, ⁴Department of Medicine, University of Alberta, Alberta, AK, ⁵Merck & Co., Inc., Whitehouse Station, NJ
Background/Purpose Axial spondyloarthritis (axSpA), including ankylosing spondylitis and nonradiographic axial SpA (nr-axSpA), is a chronic inflammatory disease marked by back pain and progressive spinal stiffness.…
Abstract Number: 1853 • 2014 ACR/ARHP Annual Meeting
Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry
Philip J. Mease¹, David Collier², Chitra Karki³, Guo Li⁴, Bojena Bitman⁵ and Jeffrey D. Greenberg^3,6, ¹Director, Rheumatology Research, Swedish Medical Center, Seattle, WA, ²Amgen, Inc., Thousand Oaks, CA, ³Corrona, LLC., Southborough, MA, ⁴Axio Research LLC, Seattle, WA, ⁵Amgen, Inc., San Francisco, CA, ⁶Rheumatology, New York University School of Medicine, New York, NY
Background/Purpose: Registry data regarding biologic DMARD therapy as a mono or combo (combined with a traditional oral DMARD) in subjects with Psoriatic Arthritis (PsA) are…
Abstract Number: 1153 • 2014 ACR/ARHP Annual Meeting
Area of Residence and Socio-Economic Factors Significantly Affect Access to Biological Therapy for Rheumatoid Arthritis Patients in Romania
Catalin Codreanu¹, Corina Mogosan², Ruxandra Ionescu³, Ioan Ancuta⁴, Magda Parvu⁵ and Simona Rednic⁶, ¹5 Thomas Masaryk Street, 'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ²'Dr. Ion Stoia' Clinical Center of Rheumatic Diseases, Bucharest, Romania, ³Rheumatology, Sfanta Maria Clinical Hospital, UMF Carol Davila, Bucharest, Romania, ⁴“Dr. I. Cantacuzino” Hospital, Bucharest, Romania, ⁵Rheumatology, Colentina Clinical Hospital, Bucuresti, Romania, ⁶Rheumatology, University of Medicine and Pharmacy, Cluj-Napoca, Romania
Background/Purpose Clinical trials have proven the efficacy of biological therapy for rheumatoid arthritis (RA) worldwide. However, high costs have set boundaries to their use, especially…
Abstract Number: 515 • 2014 ACR/ARHP Annual Meeting
Dosing of Intravenous Tocilizumab in a Real-World Setting—Analyses from a US RA Registry
Dimitrios A. Pappas¹, Ani John², Jeffrey R. Curtis³, George W. Reed^4,5, Chitra Karki⁶, Robert Magner⁵, Joel M. Kremer⁷, Ashwini Shewade² and Jeffrey D. Greenberg^6,8, ¹Columbia University, New York, NY, ²Genentech, Inc, South San Francisco, CA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Corrona, LLC., Southborough, MA, ⁵University of Massachusetts Medical School, Worcester, MA, ⁶Corrona, LLC, Southborough, MA, ⁷Albany Medical College and The Center for Rheumatology, Albany, NY, ⁸NYU School of Medicine, New York, NY
Background/Purpose: In the US, the recommended starting dose of intravenous tocilizumab (TCZ) in combination with DMARDs or as monotherapy is 4 mg/kg every 4 weeks…
Abstract Number: 2873 • 2014 ACR/ARHP Annual Meeting
Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling
Alison Maloney¹, Drew Hotson², Stephen Rapecki¹, Gianluca Fossati¹, Simon Lumb¹, David Rosen², Santosh Putta², Nikil Wale², David Spellmeyer², Alessandra Cesano², Rachael Hawtin² and Anthony Shock¹, ¹UCB Pharma, Slough, United Kingdom, ²Nodality Inc., South San Francisco, CA
Background/Purpose Epratuzumab is a humanized monoclonal antibody targeting the B cell-specific protein CD22 and is in Phase 3 clinical trials in patients with systemic lupus…
Abstract Number: 1836 • 2014 ACR/ARHP Annual Meeting
Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy
Stephen Lindsey¹, Brandi Oufnac² and Holly Walker², ¹Chief Div of Rheumatology, Ochsner Clinic Baton Rouge, Baton Rouge, LA, ²Rheumatology, Ochsner Health Systems, Baton Rouge, LA
Background/Purpose Herpes Zoster (HZ) occurs in 1 in 3 people in the U.S. during their lifetime. The greatest risk factor is age. Immune suppression from…
Abstract Number: 1146 • 2014 ACR/ARHP Annual Meeting
Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany
Christian Gissel¹, Georg Götz², Holger Repp³ and Uwe Lange⁴, ¹Rheumatology, Justus-Liebig-University Giessen, Giessen, Germany, ²Department of Economics and Business, Justus-Liebig-University Giessen, Giessen, Germany, ³Department of Medicine, Justus-Liebig-University Giessen, Giessen, Germany, ⁴Internal Medicine and Rheumatology, Justus-Liebig-University Giessen, Kerckhoff-Clinic, Bad Nauheim, Germany
Background/Purpose: In Germany, Rheumatoid Arthritis (RA) can be treated with TNF-α inhibitors after the failure of conventional disease-modifying antirheumatic drugs like Methotrexate. The clinical use…
Abstract Number: 505 • 2014 ACR/ARHP Annual Meeting
A Structured Approach for Comparative Benefit-Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis
Ani John¹, George Quartey¹, Patricia B. Lehane², Nicole Mairon³, Michael Schulte³, Ashwini Shewade¹, Carol Chung¹ and Dominic Borie¹, ¹Genentech, Inc, South San Francisco, CA, ²Roche Products Ltd, Welwyn Garden City, United Kingdom, ³F. Hoffmann-La Roche Ltd, Basel, Switzerland
Background/Purpose: Rituximab in combination with methotrexate (MTX) is indicated for the treatment of adult patients with moderate to severe active rheumatoid arthritis (RA) who have…
Abstract Number: 2740 • 2013 ACR/ARHP Annual Meeting
High Efficacy Of Toll-Like Receptor 4 Targeting In Murine and Humanized Models Of Rheumatoid Arthritis In Comparison With IL-1 and TNF Inhibitors
Shahla Abdollahi-Roodsaz¹, Marije I. Koenders², Leo A. Joosten³, Fons A. van de Loo⁴ and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³Department of Medicine, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands
Background/Purpose: Increased expression of Toll-like Receptor (TLR) 4 and its endogenous agonists in rheumatoid joints suggest involvement in rheumatoid arthritis (RA). The aim of this…
Abstract Number: 1914 • 2013 ACR/ARHP Annual Meeting
Patient and Physician Perspectives On Family Planning and Pregnancy Issues In Systemic Inflammatory Diseases: Mind The Gap!
Megan E. B. Clowse¹, Eliza Chakravarty², Daphnee S. Pushparajah³, Sarah Mertens³ and Caroline Gordon⁴, ¹Duke University Medical Center, Durham, NC, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Autoimmune and inflammatory diseases often affect women of reproductive age and can impact pregnancy outcomes. This patient (pt) group has important concerns about family…
Abstract Number: 1365 • 2013 ACR/ARHP Annual Meeting
Incidence Of Hepatitis B Virus Reactivation In Patients With Rheumatoid Arthritis During Treatment With Biologics
Jun Nakamura¹, Takao Nagashima¹, Katsuya Nagatani², Taku Yoshio³, Masahiro Iwamoto⁴ and Seiji Minota⁵, ¹Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ²Division of Rheumatology and Clinical Immunology, Jichi Medical University, Tochigi, Japan, ³Division of Rheumatology and Clinical Immunology, Jichi Medical University, School of Medicine, Shimotsuke-shi, Tochigi-ken, Japan, ⁴Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Tochigi, Japan, ⁵The Safety Evaluation Committee of Actemra® for JIA, Tokyo, Japan
Background/Purpose: Reactivation of hepatitis B virus (HBV) is very problematic in patients who are receiving biologics. Optimal precaution and management for those patients are still…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.